Objective To investigate clinical efficacy and adverse reaction of Gemcitabine combined with Lobaplatin in treatment of relapsed refractory breast cancer in advanced stage.Methods A total of 15 patients with relapsed refractory breast cancer in advanced stage during January 2013 and October 2016 underwent Gemcitabine combined with Lobaplatin chemotherapy.The patients were treated with 1000 mg/m2 Gemcitabine by intravenous infusion at 1nt and 5th days,and 35 mg/m2 Lobaplatin by intravenous infusion at 2nd day,and one chemotherapy cycle was 21d.After performing 2 cycles of chemotherapy,imaging examination was performed to evaluate the efficacy,and curative effect and adverse reaction conditions were also analyzed.Results Effective rates in patients with lymph nodes and bony metastases were high,and they reached 100％ and 71.4％ respectively,but the effect was slightly worse in patients with brain metastases.The program had a certain therapeutic effect on patients with different pathological types,hormone receptor status and hormone levels.Incidence rates of Ⅱ-Ⅳ degree leukopenia and thrombocytopenia were 26.7％ and 46.7％ respectively.The total incidence rate of nausea and vomiting was 46.7％.The total incidence rates of hair loss and dermatitis were 33.3％ and 20.0％ respectively.Liver or kidney functional damage was not found in the 15 patients.Conclusion Gemcitabine combined with Lobaplatin in treatment of patients with relapsed refractory breast cancer in advanced stage can achieve good effectiveness with good disease control rate and safety.%目的 探讨吉西他滨联合洛铂治疗晚期复发性难治性乳腺癌的临床效果及不良反应情况.方法 选取2013年1月-2016年10月收治的晚期复发性难治性乳腺癌患者15例,采用吉西他滨联合洛铂进行化疗,第1天和第5天吉西他滨1000 mg/m2静脉滴注,第2天洛铂35 mg/m2静脉滴注,21 d为1个化疗周期.完成2周期的化疗后行影像学检查评估疗效,分析其临床疗效及不良反应情况.结果 淋巴结和骨转移患者的有效率较高,分别达到了100.0％和71.4％;但对脑转移患者的疗效略差;该方案对不同病理类型、激素受体状态及激素水平的患者均具有一定的治疗效果.白细胞和血小板减少Ⅱ～Ⅳ度发生率分别为26.7％和46.7％;出现恶心、呕吐的总发生率为46.7％;脱发和皮炎的总发生率分别为33.3％和20.0％;15例患者均未出现肝、肾功能损伤情况.结论 吉西他滨联合洛铂治疗晚期复发性乳腺癌患者临床效果佳,疾病控制率高且安全性好.
展开▼
